ALK and non-small cell lung carcinoma: Gene mutations in the EGFR are detected in 10% to 15% of NSCLCs from Caucasian patients and about 30% to 40% from Asian patients,[26] ALK overexpressed in 5% of NSCLCs.[27] Due to the long 5-year survival rate of applying targeted drugs, immune therapy has been mostly applied in NSCLC patients without sensitive genes mutation, mainly the squamous cell lung carcinoma.[28,29] But targeted drugs will be resistant as the time goes.